ITEMS IN AFP WITH KEYWORD:
Although this life-threatening emergency commonly affects adults with type 2 diabetes mellitus, its incidence is increasing in children. Read the latest evidence on causes, risk factors, and complications, and get a treatment algorithm from the American Diabetes Association.
Challenges to glucose control in hospitalized patients with type 2 diabetes mellitus include determining blood glucose targets, judicious use of oral diabetes medications, and implementing appropriate insulin regimens. Home oral diabetes medications should be continued in the absence of contraindications. Insulin dosing is based on patient factors, such as current oral intake, comorbidities, baseline diabetic control, and experience with prior insulin therapy. Sliding scale insulin regimens are not recommended.
This seems like a strange question considering that the goal is to decrease mortality with drug therapy. Nevertheless, this study showed that the new kids on the diabetes block—exenatide (Byetta), dulaglutide (Trulicity), sitagliptin (Januvia), saxagliptin (Onglyza), and others—do not increase mortality, even in patients with cardiovascular risk.
Dulaglutide is an easy-to-use, once-weekly injectable therapy for the treatment of type 2 diabetes in adults. It produces a modest decrease in A1C levels with only a small risk of severe hypoglycemia. The small average weight loss it induces may be an advantage for some patients.
The American College of Physicians (ACP) previously released guidelines in 2012 regarding the effectiveness and safety of oral pharmacologic treatment for type 2 diabetes; however, new evidence has emerged and new drugs have been approved by the U.S. Food and Drug Administration. For this reason, th...
Help patients with prediabetes or diabetes achieve dietary and physical activity goals using the strategies discussed in this article.
ixisenatide is an easy-to-use, once-daily injectable therapy for the treatment of type 2 diabetes in adults. It is at least as effective as exenatide at reducing A1C and body weight, with similar rates of gastrointestinal adverse effects.
Reductions in A1C are less with albiglutide than with the first-line therapy metformin, and albiglutide costs significantly more than metformin and sulfonylureas. Albiglutide's ability to reduce diabetes-related morbidity and major cardiovascular events is unknown.
The initial Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, which compared standard treatment with intensive control, found that despite good intentions, cardiovascular (CV) and overall mortality are significantly higher when blood glucose levels are lower.
Semaglutide significantly reduced the composite outcome of CV death, nonfatal myocardial infarction, and nonfatal stroke (number needed to treat [NNT] = 43 over 2.1 years). It was generally well tolerated, and it reduced body weight by approximately 6.4 to 9.5 lb (2.9 to 4.3 kg).